glp 1 agonist diabetes How GLP-1 Receptor Agonists Evolved from to Weight Loss Treatments How GLP-1 Receptor Agonists Evolved

Abstract Traditionally, Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), a pivotal class of drug, mimics the actions of endogenous Glucagon-like peptide-1, which have been found to be remarkable in the treatment of type 2 diabetes alongside other comorbidities

Common side effects include: Gastrointestinal issues: Nausea (15-20%), vomiting (5-9%), diarrhea (8%), stomach pain (6-7%), and constipation (3-7%) Mild discomfort: Headache, dizziness, fatigue, bloating, gas, or heartburn Appetite changes: Some individuals report loss of appetite Most side effects are temporary and improve over time

Secondary data was analyzed to arrive at the overall size of the global GLP-1 agonists market, which was validated through primary research

Hypoglycemia: Low blood sugar, especially when taken with other diabetes medications like insulin or sulfonylureas

There are also several distinctions

There was a reduction in plasma glucose and HbA1c levels at the three highest doses of retatrutide and a dose-dependent reduction in body weight [63]